Sent this to the 60 minute tip line at CBS yesterday...

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps
1,130
Sent this to the 60 minute tip line at CBS yesterday...


Covid Life Saving Drug caught in Politics?

There is a drug that is receiving little recognition for its science. It’s a small biotech drug company that had the support of a lab that recommended it to try its monoclonal antibody as a Covid-19 drug.

The owner of the lab business named IncellDX is a former Stanford professor of virology and has written 150 published medical Papers during his career. He has submitted a covid-19 medical paper on Leronlimab stating the science and Best possible drug for Covid-19 and said it was like this drug was designed for Covid-19 in its mechanism of action and how it responds to the virus.

Today he was on a YouTube video being interviewed by Doctor Yo. Who has interviewed him a number of times. Today was different as Dr. Patterson was on to speak of Phase 2 trial information for Leronlimab that was released today by the Biotech company Cytodyn.

Dr. Patterson said this was the only drug thus far that has tested positively with science backed results of helping the patients in many ways. He gave his opinion on that he thought it would make a good argument for Emergency Use Approval. ( My opinion is we could be saving literally thousands of lives when this drug is approved) Dr Yo asked him why this drug gets little to no main stream media and why so many bashers are plaguing this company. He also asked how do we get you on a bigger platform so America and the world can see what you have to say? Dr. Patterson stated that he somehow found out that some POLITICS were involved in his medical paper being published. He said he has found this out behind the scenes and will deal with it behind the scenes. He wouldn’t speak anymore to it.

My thought and the story I believe is happening here is two fold. One that big pharma controls the FDA and pressures also the medical journals. Our government use to do all the testing of drugs and now we trust big pharma to police them self’s. It’s like the Fox gets to watch the hen house. It leads to hidden agendas that only promote the big companies like a good ol’ boys club.

The other thought which I hate to think there is something or someone In the White House stopping this life saving drug from market and saving thousands of lives. The only one who can say who is behind the politics of the hold up of a ground breaking medical publishing from the New England Journal of Medicine or the likes. Is Doctor Bruce Patterson. Former Stanford professor of virology. Owner of IncellDX With 150 medical published paper and highly respected by all his peers. He has the story that should be told. A conspiracy story for the ages. That’s what it is! Conspiracy of the ages.

Please investigate and see if you can find out who would allow thousands of people to die DAILY just so they could make more money. There is someone that needs to pay for the lives that are being lost. Please find that person(s) and make them pay.


Thank you for reading!


Xxxxx. Xxxxxxx
Xxx-xxx-xxxx

PS

Here is the video when he states the politics behind the scenes statement. ALSO find Dr Patterson Tedx talk on Leronlimab for additional research about a month ago of how effective this drug has been in emergency use. Before it was stopped.

https://www.youtube.com/watch?v=horRSvu6xAk

https://youtu.be/tPMHZiR_htQ

Read More: https://investorshangout.com/messages/view?id...z6V3ZNFImY

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

SKK Holdings Limited Announces Pricing for Share IPO Offering

Updated Category News Views 65

SKK Holdings Limited Announces Share Pricing for IPO SKK Holdings Limited (“SKK” or the “Company”) (Nasdaq: SKK), a specialized civil engineering service provider in subsurface utility works, has proudly announced the pricing of its initial public offering. The Company will offer 2,500,000 ordinary shares at a public offering price of $4.00 per share, yielding...

Continue Reading
Antelope Enterprise: Financial Performance Insights for 2024

Updated Category News Views 149

Antelope Enterprise Holdings Limited (NASDAQ: AEHL) hit the financial report stage hard back in mid-2024, flaunting numbers that tell quite the tale of both triumphs and tribulations. This company was hustling across two growing fronts: the fast-paced world of livestreaming ecommerce and the burgeoning energy sector down in Texas. Their half-year performance review...

Continue Reading
Olivier Falut Steps Into CFO Role at EUROAPI to Drive Growth

Updated Category News Views 344

Olivier Falut Joins EUROAPI as the New Chief Financial Officer EUROAPI is excited to announce the appointment of Olivier Falut as its new Chief Financial Officer, effective immediately. Olivier will be an integral member of the Executive Committee, succeeding Evelyne Nguyen. Evelyne will ensure continuity and a smooth transition within the company through her support...

Continue Reading
OPEXUS and Casepoint Join Forces for Growth and Innovation

Updated Category News Views 261

OPEXUS and Casepoint Unite for Strategic Growth In a significant development in the technology sector, OPEXUS, a frontrunner in government process management software, and Casepoint, an innovator in data discovery technology, have announced their merger. This significant move comes along with a majority investment from Thoma Bravo, a renowned software investment firm...

Continue Reading
MeiraGTx Holdings: An In-Depth Look at Future Potential

Updated Category News Views 69

MeiraGTx Holdings plc (NASDAQ:MGTX) was a clinical-stage gene therapy firm making waves back in 2024. The company announced a pivotal financial move, securing $50 million through equity financing at $4 per share, largely thanks to a $30 million investment from Sanofi (NYSE:SNY). While this funding boosted MGTX’s war chest, traders were already whispering about the heavy...

Continue Reading